_2020091018165303jzv.jpg "Decoding The World Of ETF")
-
My Account
My Account
BSE Live
Nov 27, 16:00Prev. Close
4898.80
Open Price
4898.80
Bid Price (Qty.)
4829.60 (651)
Offer Price (Qty.)
4829.60 (5)
NSE Live
Nov 27, 15:59Prev. Close
4901.35
Open Price
4901.00
Bid Price (Qty.)
4828.95 (5190)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Dr Reddys Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 83.10 | 83.00 | 83.00 | 82.90 | 85.30 | |
| Total Share Capital | 83.10 | 83.00 | 83.00 | 82.90 | 85.30 | |
| Reserves and Surplus | 15,108.80 | 12,601.10 | 11,724.80 | 11,517.70 | 11,520.10 | |
| Total Reserves and Surplus | 15,108.80 | 12,601.10 | 11,724.80 | 11,517.70 | 11,520.10 | |
| Total Shareholders Funds | 15,191.90 | 12,684.10 | 11,807.80 | 11,600.60 | 11,605.40 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 19.30 | 345.40 | 488.00 | 485.20 | 994.40 | |
| Deferred Tax Liabilities [Net] | 0.00 | 55.50 | 0.00 | 0.00 | 35.50 | |
| Other Long Term Liabilities | 29.60 | 28.50 | 31.30 | 41.10 | 57.10 | |
| Long Term Provisions | 54.50 | 54.70 | 53.30 | 62.30 | 66.50 | |
| Total Non-Current Liabilities | 103.40 | 484.10 | 572.60 | 588.60 | 1,153.50 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 1,043.60 | 546.30 | 2,100.80 | 1,869.90 | 2,089.60 | |
| Trade Payables | 1,068.40 | 1,031.60 | 1,061.00 | 778.70 | 719.20 | |
| Other Current Liabilities | 1,861.20 | 1,316.70 | 1,384.70 | 1,401.00 | 1,409.50 | |
| Short Term Provisions | 207.30 | 184.70 | 173.40 | 208.40 | 580.40 | |
| Total Current Liabilities | 4,180.50 | 3,079.30 | 4,719.90 | 4,258.00 | 4,798.70 | |
| Total Capital And Liabilities | 19,475.80 | 16,247.50 | 17,100.30 | 16,447.20 | 17,557.60 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 3,769.80 | 3,950.40 | 3,979.00 | 4,043.30 | 3,593.80 | |
| Intangible Assets | 664.10 | 732.30 | 738.30 | 798.80 | 835.50 | |
| Capital Work-In-Progress | 384.10 | 400.10 | 675.00 | 540.00 | 615.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 4,845.70 | 5,082.80 | 5,392.30 | 5,382.10 | 5,044.30 | |
| Non-Current Investments | 3,367.10 | 1,819.10 | 1,953.70 | 1,802.80 | 1,776.10 | |
| Deferred Tax Assets [Net] | 612.90 | 0.00 | 93.10 | 82.10 | 0.00 | |
| Long Term Loans And Advances | 1.20 | 33.20 | 199.10 | 193.20 | 639.60 | |
| Other Non-Current Assets | 542.20 | 379.20 | 423.60 | 393.20 | 2.70 | |
| Total Non-Current Assets | 9,369.10 | 7,314.30 | 8,061.80 | 7,853.40 | 7,462.70 | |
| CURRENT ASSETS | ||||||
| Current Investments | 2,118.40 | 2,114.40 | 1,682.80 | 1,299.10 | 2,112.20 | |
| Inventories | 2,190.40 | 2,015.60 | 1,856.80 | 1,809.70 | 1,699.60 | |
| Trade Receivables | 4,638.70 | 3,717.70 | 4,203.80 | 4,405.40 | 3,893.50 | |
| Cash And Cash Equivalents | 39.20 | 113.20 | 120.70 | 66.70 | 1,268.00 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 832.60 | |
| OtherCurrentAssets | 1,120.00 | 972.30 | 1,174.40 | 1,012.90 | 289.00 | |
| Total Current Assets | 10,106.70 | 8,933.20 | 9,038.50 | 8,593.80 | 10,094.90 | |
| Total Assets | 19,475.80 | 16,247.50 | 17,100.30 | 16,447.20 | 17,557.60 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1,068.60 | 696.50 | 716.70 | 707.90 | 972.60 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 1,200.30 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 204.70 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 3,961.60 | 1,910.40 | 1,891.60 | 0.00 | 1,306.50 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | 7,262.30 | -- | 7,261.80 | |
| Other Earnings | 8,419.30 | 8,867.30 | -- | -- | 278.70 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 55.87 | 55.87 | 55.87 | 55.87 | 55.87 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 1.10 | 3.80 | 3.00 | 3.50 | 2.30 | |
| Non-Current Investments Unquoted Book Value | 5,546.60 | 4,033.00 | 135.40 | -- | 1,968.80 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | 1,682.80 | 1,299.10 | 2,112.20 |
04.11.2020
Buy Dr Reddy's Laboratories; target of Rs 6000: ICICI Direct
04.11.2020
Accumulate Dr. Reddy’s laboratories; target of Rs 5418 KR Choksey
03.11.2020
Accumulate Dr Reddy's Laboratories; target of Rs 5414: Dolat Capital Market
03.11.2020
Buy Dr. Reddy's Laboratories; target of Rs 5964: Prabhudas Lilladher
29.10.2020
Dr Reddys Labs Consolidated September 2020 Net Sales at Rs 4,910.90 crore, up 2.04% Y-o-Y
29.10.2020
Dr Reddys Labs Standalone September 2020 Net Sales at Rs 3,345.80 crore, down 2.91% Y-o-Y
28.10.2020
Dr Reddy's Labs Q2 profit falls 30% to Rs 762 crore, global generics business up 21%
29.08.2020
29.07.2020
Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%
14.10.2019
12.07.2019
Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher
17.05.2019
Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23%
